logo-loader
viewPuma Biotechnology Inc

Puma Biotechnology shares gain on NERLYNX approval news

The drug is expected to hit the market in September and is used after traditional treatment to avoid recurrence of the condition..

shutterstock_439844257.jpg
One in four patients experience recurrence after treatment, but studies of its drug had shown a 34% reduction in recurrence, said the group

Puma Biotechnology Inc (NASDAQ: PBYI) shares gained almost 9% to $93.72 after unveiling highly positive drug development news.

The US FDA have approved of NERLYNX for the extended  treatment of HER2-positive early stage breast cancer, the firm reported.

The drug is expected to hit the market in September and is used after traditional treatment to avoid recurrence of the condition.

Puma said up to one in four patients experience recurrence after treatment, but studies of its drug had shown a 34% reduction in recurrence.

"The fear of recurrence is ever present in the minds of most women with breast cancer, from the moment they are diagnosed to long after they finish adjuvant treatment," said Marisa C. Weiss, chief medical officer and founder of Breastcancer.org.

“New and effective innovative therapeutic options provide huge hope to patients and their families, giving them a better chance of overcoming breast cancer with a chance for a full life.”

Shares in the firm have gained more than 117% in the past three months.

Quick facts: Puma Biotechnology Inc

Price: 10.69 USD

NASDAQ:PBYI
Market: NASDAQ
Market Cap: $420.81 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Chesapeake Financial Shares has a strong balance sheet as they adapt in...

Chesapeake Financial Shares (OTCQX - CPKF) CEO Jeff Szyperski joined Steve Darling from Proactive to report on the company’s 2nd quarter financial numbers. Szyperski talks about how the company has done in dealing with the COVID-19 outbreak. Szyperski also told Proactive about the...

1 hour, 44 minutes ago

2 min read